Moderna, Inc. (NASDAQ:MRNA) showcased its expanding vaccine portfolio during its fourth annual Vaccines Day, highlighting progress in developing vaccines against various pathogens. The event covered updates on key vaccine programs, including the CMV and EBV vaccines, and discussed the commercial potential of its respiratory portfolio, estimated at $27 billion per year. Moderna also emphasized its innovative use of AI in vaccine development and outlined its financial strategy, including a focus on reinvesting in the business and exploring project financing options.